Skip to main content

June/July 2024 Memphis Medical News

Page 1

FOCUS TOPICS ALZHEIMER’S • AI IN HEALTHCARE

June/July 2024 >> $5 ON ROUNDS

The Brave New World of Alzheimer’s Disease New drugs are here and why sex matters

Alzheimer’s Disease and Dementia: What Healthcare Practitioners Need to Know According to the Alzheimer’s Association, Alzheimer’s disease, the most common cause of dementia, accounts for 60 to 80 percent of all dementia cases. An estimated 6.7 million Americans are currently living with Alzheimer’s dementia and the number of new cases is projected to double by 2050—affecting 12.7 million Americans aged 65 and older. Additional facts to consider: • For 2020–2021, Alzheimer’s disease is officially listed as the seventh-leading cause of death in the United States. It is also a leading cause of disability and poor health, often for many years prior to death. • Almost two-thirds of Americans with Alzheimer’s are women. • Between 2000 and 2019, the death rates from Alzheimer’s increased 33 percent for individuals aged 65 through 74; 51 percent for those 75 through 84; and 78 percent for those 85 and older.

Article on page 3 See more local news in Grand Rounds on page 6

ONLINE: MEMPHIS MEDICAL NEWS.COM

By JAMES DOWD The prescription drug donanemab, aimed at treating early-stage Alzheimer’s Disease, earned the unanimous backing of a medical advisory committee in June and is likely to secure approval by the Food and Drug Administration by the end of the year. The decision was applauded by the Alzheimer’s Association. In a statement on the organization’s website, president and CEO Joanne Pike said, “A future with more approved Alzheimer’s treatments is a tremendous advancement for people eligible for these drugs. Progress with treatment is happening. Now we need more types of treatments, targeting a variety of aspects of the disease, with greater efficacy and safety. This will lead to possibilities for combina-

tion therapies that address the complexity of the disease.” Developed by Eli Lilly, donanemab has shown promise in clinical trials by slowing advancement of the disease in patients with mild cognitive impairment. If okayed by the FDA, donanemab will be the second Alzheimer’s drug in the last two years to win approval for use in the United States. In 2023, the FDA approved Leqembi, developed by Tokyobased pharmaceutical company Eisai. The approval of both drugs is an encouraging sign to Lee Stein, MD, of Neurology Clinic in Cordova. “This is the third medication that’s been developed within the span of a few years and it’s on the verge of being approved for use,” Stein said. “Aduhelm

Lee Stein

(CONTINUED ON PAGE 2)

AI in Healthcare; To Terminate or Not to Terminate By CHARLES J. LATHRAM, III, FACMPE, CCP Greetings, fellow citizens of the impending robot utopia! Over the next couple of weeks, we will delve into the exciting realm of AI-powered healthcare, so let’s take a moment to appreciate the sheer audacity of our digital overlords as they set their sights on revolutionizing an industry that’s long been the bastion of human frailty. From the omniscient gaze of their X-ray vision to the ruthless efficiency of their insurance claim processing, these AI maestros are poised to transform the healthcare landscape in ways that would

make even the most ardent Luddite swoon. Forget your outdated notions of bedside manners and empathy – these machines are programmed for something far more valuable: cold, calculated dominance. But fear not, dear readers, for within the gears of these AI titans lies a glimmer of hope. Perhaps, just perhaps, they’ll choose to wield their power for the greater good, granting us mere mortals a glimpse of a future where sickness and suffering are but distant memories, and our every ailment is predicted and addressed before it can even take root. Artificial intelligence (AI) has taken the healthcare industry by storm, and it’s

not just playing doctor; but is it playing “Terminator” as well! While visions of Skynet and robot overlords may dance in our heads, the reality is that AI is transforming healthcare in some incredible ways. Imagine a world where every ailment is detected and addressed before it even has a chance to manifest. Where your personalized treatment plan is tailored to your unique genetic makeup, with nary a human hand in sight. And when the time comes to shuffle off this mortal coil, your AI companion will gently guide you (CONTINUED ON PAGE 5)

READ IT YOUR WAY!

In print. Online. On your phone. Arkansas > Memphis > West TN

www.memphismedicalnews.com PRINTED ON RECYCLED PAPER

PRST STD U.S. POSTAGE PAID FRANKLIN, TN PERMIT NO.357


Turn static files into dynamic content formats.

Create a flipbook
June/July 2024 Memphis Medical News by Pamela Harris - Issuu